Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures

Neuroscience Letters

Volumn 481, Issue 2, 2010, Pages 78-81

  Matsuo, Takaaki ^a   Izumi, Yasuhiko ^a   Kume, Toshiaki ^a   Takada Takatori, Yuki ^b   Sawada, Hideyuki ^c   Akaike, Akinori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^c UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

Aripiprazole; Dopamine; Glutamate cytotoxicity; Intracellular dopamine content; Neuroprotective effect

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; SULPIRIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 77955273845     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.049     Document Type: Article

References (24)

1. 2 receptors. J. Pharmacol. Exp. Ther. 2002, 302:381-389.
2. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
3. 1A receptor activation. Brain Res. 2005, 1043:32-41.
4. Doherty M.D, Pickel V.M. Targeting of serotonin 1A receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain. J. Comp. Neurol. 2001, 433:390-400.
5. Eren I., Naziroĝlu M., Demirdaş A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 2007, 32:1188-1195.
6. Fernandez H.H., Trieschmann M.E., Friedman J.H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin. Neuropharmacol. 2004, 27:4-5.
7. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur. J. Pharmacol. 2007, 557:132-140.
8. Izumi Y., Yamamoto N., Kume T., Katsuki H., Sawada H., Akaike A. Regulation of intracellular dopamine levels by dopaminergic drugs: involvement of vesicular monoamine transporter. Eur. J. Pharmacol. 2008, 582:52-61.
9. Izumi Y., Yamamoto N., Matsuo T., Wakita S., Takeuchi H., Kume T., Katsuki H., Sawada H., Akaike A. Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J. Neurochem. 2009, 110:745-755.
10. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 1995, 274:329-336.
11. Kitao Y., Imai Y., Ozawa K., Kataoka A., Ikeda T., Soda M., Nakimawa K., Kiyama H., Stern D.M., Hori O., Wakamatsu K., Ito S., Itohara S., Takahashi R., Ogawa S. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 2007, 16:50-60.
12. López-Meza E., Ruiz-Chow A., Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 2005, 17:421-422.
13. Madhavan L., Freed W.J., Anantharam V., Kanthasamy A.G. 5-hydroxytryptamine 1A receptor activation protects against N-methyl-d-aspartate-induced apoptotic cell death in striatal and mesencephalic cultures. J. Pharmacol. Exp. Ther. 2003, 304:913-923.
14. Matsuo T., Izumi Y., Wakita S., Kume T., Takada-Takatori Y., Sawada H., Akaike A. Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: implication of inhibition of vesicular transport. Eur. J. Pharmacol. 2010, 640:68-74.
15. 1A receptor agonist BAY x 3702 in vitro and in vivo. Brain Res. 2001, 888:150-157.
16. 1A receptor agonist 8-OH-DPAT. Eur. J. Pharmacol. 1998, 358:147-152.
17. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., Kim Y.H. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol. 2009, 19:356-362.
18. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 1998, 44:S175-S188.
19. Sakka N., Sawada H., Izumi Y., Kume T., Katsuki H., Kaneko S., Shimohama S., Akaike A. Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport 2003, 14:2425-2428.
20. Sawada H., Kawamura T., Shimohama S., Akaike A., Kimura J. Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J. Neurosci. Res. 1996, 43:503-510.
21. 2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 1998, 44:110-119.
22. Singh Ajit S. Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease?. J. Neuropsychiatry Clin. Neurosci. 2007, 19:205-206.
23. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8:600-606.
24. Yang T.T., Wang S.J. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse 2008, 62:804-818.